Knight Therapeutics reported strong financial performance with record revenues and EBITDA, significant growth driven by key products, and an improved financial outlook for 2025. The expansion of the oncology portfolio and increased credit facility provide a solid foundation for future growth. However, challenges were noted with regulatory setbacks in Brazil and Canada and a financial asset loss, though these do not overshadow the overall positive trends and achievements.

Company Guidance

In the third quarter of 2025, Knight Therapeutics reported record adjusted revenues of $122.6 million, marking a 34% increase over the same period last year, with a constant currency revenue growth of 31%. The company achieved an adjusted EBITDA of $21 million, a 56% rise from the previous year, and an adjusted EBITDA per share increase of 62% to $0.21. This growth was driven by the Paladin and Sumitomo transactions, which contributed $25 million in incremental revenues, and a 15% increase in key oncology products like AKYNZEO and MINJUVI. The company also saw a 127% increase in revenues within its specialty therapeutic area, largely due to the Paladin and Sumitomo portfolios. Despite setbacks with regulatory approvals in Brazil and Canada, Knight aims to address these and has raised its 2025 revenue guidance to between $430 million and $440 million, with an adjusted EBITDA margin of 13.5% to 14.5%.

Record High Adjusted Revenues and EBITDA

Knight Therapeutics achieved record high adjusted revenues of $319 million and adjusted EBITDA of approximately $49 million for the nine months ended September 30, 2025. Revenues grew by $48 million or 18% compared to the same period last year.

Revenue Growth from Key Products

Revenues were driven by the Paladin and Sumitomo transactions, which contributed $27 million of incremental revenues, and key promoted products delivered organic growth of 12% on a constant currency basis.

Expansion of Oncology Portfolio

Knight expanded its partnership with Incyte by in-licensing the LatAm rights to two innovative drugs, retifanlimab and axatilimab, and launched several products including JORNAY PM in Canada, MINJUVI in Argentina, and PEMAZYRE in Brazil and Mexico.

Increased Financial Outlook for 2025

Knight increased its financial outlook for fiscal 2025, expecting revenues between $430 million and $440 million, and an adjusted EBITDA between 13.5% to 14.5% of revenues.

Increased Credit Facility

Knight doubled its revolving credit facility from USD 50 million to USD 100 million, with an accordion feature for another USD 100 million, providing increased financial flexibility.

Knight Therapeutics (TSE:GUD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:GUD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 19, 2026	2025 (Q4)	-0.01 / -	0.11	―	―	―
Nov 06, 2025	2025 (Q3)	>-0.01 / -0.04	0	―	―
Aug 07, 2025	2025 (Q2)	0.02 / -0.13	-0.02	-550.00% (-0.11)	―
May 08, 2025	2025 (Q1)	<0.01 / 0.02	-0.04	150.00% (+0.06)	―
Mar 20, 2025	2024 (Q4)	0.02 / 0.11	-0.23	147.83% (+0.34)	―
Nov 07, 2024	2024 (Q3)	0.02 / 0.00	0.09	―	―
Aug 08, 2024	2024 (Q2)	0.02 / -0.02	0.02	-200.00% (-0.04)	―
May 09, 2024	2024 (Q1)	0.01 / -0.04	-0.04	0.00% (0.00)	―
Mar 21, 2024	2023 (Q4)	-0.01 / -0.23	-0.13	-76.92% (-0.10)	―
Nov 09, 2023	2023 (Q3)	-0.03 / 0.09	0.01	800.00% (+0.08)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:GUD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	C$5.84	C$6.07	+3.94%
Aug 07, 2025	C$6.29	C$6.40	+1.75%
May 08, 2025	C$6.07	C$5.68	-6.43%
Mar 20, 2025	C$6.25	C$6.27	+0.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Knight Therapeutics (TSE:GUD) report earnings?

Knight Therapeutics (TSE:GUD) is schdueled to report earning on Mar 19, 2026, Before Open (Confirmed).

What is Knight Therapeutics (TSE:GUD) earnings time?

Knight Therapeutics (TSE:GUD) earnings time is at Mar 19, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:GUD EPS forecast?

TSE:GUD EPS forecast for the fiscal quarter 2025 (Q4) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing